Assistant Professor Washington University in St. Louis School of Medicine Saint Louis, Missouri, United States
This workshop underscores the value of early testing for biomarkers of disease progression in patients with hormone receptor-positive metastatic breast cancer. ESR1 mutations have been identified as influential factors that can lead to decreased effectiveness of therapy and clinical progression. Testing of ESR1 mutations may proactively detect endocrine therapy resistance before radiologic progression occurs.
